Study supports drug-eluting stents for STEMI patients

08/19/2013 | TCTMD.com

Drug-eluting stents beat bare-metal stents for reducing target vessel revascularization without raising the risk of stent thrombosis in STEMI patients, according to a meta-analysis published in Circulation: Cardiovascular Interventions. Researchers analyzed data from clinical trials involving 14,740 STEMI patients. "The totality of data with results from cohorts, including non-acute coronary syndrome patients, patients with diabetes mellitus, and now patients with STEMI, suggest that DES (especially EES) should be the benchmark for both efficacy and safety for future clinical trials," the authors wrote.

View Full Article in:

TCTMD.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD